Should You Ditch GlaxoSmithKline plc And Buy Vectura Group PLC And SkyePharma PLC?

Are these 2 pharmaceutical stocks better buys that GlaxoSmithKline plc (LON: GSK)? Check out Vectura Group PLC (LON: VEC) and SkyePharma PLC (LON: SKP).

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

With the stock market having been akin to a rollercoaster ride so far in 2016, many investors are understandably seeking out defensive stocks. This makes sense because a volatile portfolio is never much fun and can lead to a great deal of worry and the potential for sleepless nights.

One stock that offers defensive characteristics is GlaxoSmithKline (LSE: GSK). Part of the reason for this is the fact that its profitability is less positively correlated to the performance of the global economy than is the case for most of its FTSE 100 peers. In other words, GlaxoSmithKline depends less on GDP growth and more on a strong drugs pipeline for its bottom-line growth. As such, even if there’s further volatility in share prices, GlaxoSmithKline could continue to outperform the FTSE 100, as it has done since the turn of the year, by over 5%.

In addition, GlaxoSmithKline also pays a superb dividend. It currently yields 5.8% and although dividends are due to flatline over the next couple of years as the company implements a major restructuring programme, its shareholder payouts remain relatively high and consistent. During a period of uncertainty this is a superb ally for nervous investors.

As well as defensive attributes, GlaxoSmithKline also has a strong pipeline of new drugs that have the potential to rapidly increase its sales and profit over the medium-to-long term. In fact, GlaxoSmithKline’s portfolio is one of the most diversified in the business and it has real potential to generate multiple blockbuster drugs, with its ViiV Health Care subsidiary being of key importance to the company’s long-term growth. And with its bottom line due to be positively impacted by cost cuts, GlaxoSmithKline seems to be an excellent buy for the long term.

What’s the alternative?

Of course, it’s not the only stock in the pharmaceutical sector that could be worth adding to your portfolio. In fact, there are a number of companies that offer tremendous forecast growth rates and yet trade on highly appealing valuations.

For example, airways diseases specialist Vectura (LSE: VEC) is forecast to increase its bottom line by 116% in the next financial year following what’s expected to be a profitable year in 2016. And with its shares trading on a price-to-earnings (P/E) ratio of 53, this equates to a price-to-earnings growth (PEG) ratio of only 0.5. This indicates that they could deliver improved performance following their fall of 8% in the last six months.

Similarly, drug delivery specialist SkyePharma (LSE: SKP) is due to post a rise in its bottom line of 51% in 2016. When combined with its P/E ratio of 25.6, this equates to a PEG ratio of only 0.5 and indicates that there’s considerable upside potential. As with Vectura, SkyePharma pays no dividend and isn’t expected to commence shareholder payouts this year. In addition, the two companies are much smaller than GlaxoSmithKline and arguably offer less defensive characteristics or stability, but do have greater growth potential.

As such, a mix of all three stocks seems to be a sound move, although for investors who are only able to buy one of the three companies, GlaxoSmithKline appears to have the perfect mix of growth, income and defensive qualities.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter Stephens owns shares of GlaxoSmithKline. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Affectionate Asian senior mother and daughter using smartphone together at home, smiling joyfully
Investing Articles

How I’d invest my first £20k ISA to target £4,900 a year from dividend shares

Looking for dividend shares in a new Stocks and Shares ISA, and want diversification too? Here's how I'd go about…

Read more »

Passive income text with pin graph chart on business table
Investing Articles

Yields of up to 7%! I’d consider boosting my income with these FTSE dividend stocks

The London market has some decent-looking dividend stocks right now, and I’m tempted by these two for growing income streams.

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

I’d put £20K in an ISA now to target a £1,900 monthly second income in future!

Christopher Ruane shares why he thinks a long-term approach to investing and careful selection of shares could help him build…

Read more »

Mature couple at the beach
Investing Articles

6 stocks that Fools have been buying!

Our Foolish freelancers are putting their money where their mouths are and buying these stocks in recent weeks.

Read more »

Black woman using loudspeaker to be heard
Investing Articles

I was right about the Barclays share price! Here’s what I think happens next

Jon Smith explains why he still feels the Barclays share price is undervalued and flags up why updates on its…

Read more »

Investing Articles

Where I’d start investing £8,000 in April 2024

Writer Ben McPoland highlights two areas of the stock market that he would target if he were to start investing…

Read more »

View of Tower Bridge in Autumn
Investing Articles

Ahead of the ISA deadline, here are 3 FTSE 100 stocks I’d consider

Jon Smith notes down some FTSE 100 stocks in sectors ranging from property to retail that he thinks could offer…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Why I think Rolls-Royce shares will pay a dividend in 2024

Stephen Wright thinks Rolls-Royce shares are about to pay a dividend again. But he isn’t convinced this is something investors…

Read more »